复方玄驹胶囊治疗自身免疫性前列腺炎大鼠的实验研究

Therapeutic efficacy of Compound Xuanju Capsule on autoimmune prostatitis in rats:An experimental study

目的:研究复方玄驹胶囊对自身免疫性前列腺炎大鼠的治疗效果。方法:健康Wistar大鼠60只,随机分为5组,对照组、低浓度蛋白免疫模型组、低浓度蛋白免疫+复方玄驹胶囊全方治疗组、高浓度蛋白免疫模型组、高浓度蛋白免疫+复方玄驹胶囊全方治疗组。除对照组外,其余4组用高低两种浓度(15 mg/ml及80 mg/ml)的同种大鼠前列腺匀浆蛋白提纯液进行注射造模。造模(30 d)成功后,对照组和模型组生理盐水[1 ml/(200 g·d)]灌胃,治疗组用生理盐水溶解的复方玄驹胶囊全方[0.068 g/(ml·d)]灌胃,随后分别于30、45、60 d分批处死大鼠。用ELISA法检测大鼠血清中的IL-8、IL-10及TNF-α的表达,并观察大鼠前列腺组织病理切片。结果:与模型组相比,经复方玄驹胶囊全方灌胃治疗的高浓度蛋白免疫大鼠血清中IL-8、TNF-α在造模45 d时由(148.54±17.23)pg/ml、(62.14±5.59)pg/ml下降到(100.77±11.08)pg/ml、(32.63±2.91)pg/ml(P<0.05);60 d时由(143.69±17.28)pg/ml、(59.38±5.50)pg/ml降到(95.77±10.53)pg/ml、(29.63±2.66)pg/ml(P<0.05)。低浓度组造模45 d时IL-8、TNF-α亦由(128.47±12.21)pg/ml、(40.43±3.64)pg/ml下降至(111.76±10.07)pg/ml、(35.44±3.17)pg/ml(P<0.05),60 d时由(131.07±10.93)pg/ml、(43.34±3.91)pg/ml降至(97.46±8.75)pg/ml、(30.44±2.75)pg/ml(P<0.05)。高浓度蛋白免疫的治疗组大鼠血清IL-10在造模45 d、60 d分别由(189.14±16.78)pg/ml、(184.14±15.89)pg/ml上升至(230.48±29.96)pg/ml、(248.48±31.03)pg/ml(P<0.05),低浓度组由(223.14±17.87)pg/ml、(224.14±17.93)pg/ml升高至(231.42±23.18)pg/ml、(249.42±24.97)pg/ml(P<0.05)。病理切片示对照组无明显变化;实验组病理切片显示大鼠前列腺组织腺体结构破坏,炎性细胞浸润;治疗组治疗15 d后光镜下观察病变逐步改善,腺腔增大,上皮细胞轻度增生,间质中无明显炎性细胞浸润,可见少量纤维组织。结论:复方玄驹胶囊能降低自身免疫性前列腺炎大鼠前列腺组织炎性改变,并有效改善炎性因子表达,对大鼠自身免疫性前列腺炎有一定疗效。

Objective ： To evaluate the therapeutic effect of Compound Xuanju Capsule （CXC） on autoimmune prostatitis in rat models. Methods ： Sixty healthy male Wistar rats were randomly divided into five groups of equal number： blank control, low-concen- tration purified prostate protein （low-conc PPP）, low-conc PPP ＋ CXC treatment, high-concentration PPP （hi-con PPP）, and hi- conc PPP ＋ CXC treatment. Autoimmune prostatitis models were established by intragastric administration of PPP solution at 15 rag/ ml （low concentration） and 80 mg/ml, respectively. At 30 days after modeling, the rats in the blank control and low-conc and hi-conc PPP model groups were treated with normal saline, and those in the other two groups with CXC at a daily dose of 0. 068 g/ml. At 30, 45, and 60 days, all the animals were sacrificed for observation of pathological changes in the prostate tissue and determination of the levels of IL-8, IL-10, and TNF-α in the serum. Results ： Compared with the PPP models, the hi-conc PPP ＋ CXC group showed significantly reduced levels of IL-8 and TNF-α in the serum at 45 days （ [ 148.54 ±17.23] and [62.14 ±5.59] pg/ml vs [ 100.77 ± 11.08] and [32.63 ±2.91] pg/ml, P〈0.05） and at60 days （[143.69±17.28] and [59.38±5.50] pg/ml vs [95.77 ±10.53] and [29.63 ±2.66] pg/ml, P〈0.05）, and so did the low-cone PPP ＋ CXC group at45 days （[128.47 ±12.21] and [40.43 ± 3.64] pg/ml vs [111.76 ±10.07] and [35.44 ±3.17] pg/ml, P 〈0.05） and at 60 days （ [131.07 ±10.93] and [43.34 ±3.91] pg/ml vs [ 97.46 ± 8.75 ] and [ 30.44 ± 2.75 ] pg/ml, P 〈 0. 05 ）. The serum level of IL-10 was remarkably elevated in the hi-cone PPP ＋ CXC group as compared with that of the PPP models at 45 and 60 days （ [ 189.14 ± 16.78] and [ 184.14 ± 15.89] pg/ml vs [230.48 ±29.96] and [248.48 ±31.03] pg/ml, P 〈0.05）, and so was it in low-cone PPP ＋ CXC group （ [223.14 ＋ 17.87] and [ 224.14 ± 17.93 ] pg/ml vs [ 231.42 ± 23.18 ] and [ 249.42 ± 24.97 ] pg/ml, P 〈 0.05 ）. Pathological examination revealed mor- phologieal damages to the prostate tissue and infiltration of inflammatory cells in the model rats, but no obvious changes in the normal controls. At 15 days of treatment, the rats in the PPP ＋ CXC group showed enlarged prostate glandular cavity, mild proliferation of ep- ithelial cells, no obvious infiltration of inflammatory cells in the interstitial tissue, and a few visible fibrous tissues under the light mi- croscope. Conclusion ： Compound Xuanju Capsule is efficacious on autoimmune prostatis in rats by reducing inflammatory changes in the prostate tissue and improving the expression of inflammatory factors. Natl J Androl, 2014, 20 （5） ： 442 -447